Sumitomo Chemical India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SUMICHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sumitomo Chemical India reported strong Q1 FY26 results with standalone revenue from operations rising ~26% year-on-year to ₹1,048.07 crore (vs ₹831.78 crore in Q1 FY25). Standalone profit after tax grew ~40% YoY to ₹179.81 crore (vs ₹128.39 crore), translating to an EPS of ₹3.60 (vs ₹2.57). Consolidated revenue came in at ₹1,056.78 crore with consolidated PAT of ₹178.10 crore, again reflecting ~26% revenue and ~40% PAT growth YoY. Margins also expanded, with PAT margin moving from ~15.4% to ~17.2% on a standalone basis. The board meeting lasted just 34 minutes, and BSR & Co. LLP issued an unmodified limited review report. The company reiterated that its business is seasonal and monsoon-dependent, and noted an ongoing Delhi High Court challenge to the 2022 glyphosate usage notification.
Strong double-digit revenue and profit growth, along with margin expansion, are positive signals for shareholders and likely supportive of the stock. Investors should note the seasonal nature of agrochemical demand (Q1 is typically a strong quarter post-sowing), and watch the glyphosate regulatory outcome as it remains a material product for the company.